TY - JOUR
T1 - The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches
T2 - A European expert recommendation
AU - Schnell, Oliver
AU - Alawi, Hasan
AU - Battelino, Tadej
AU - Ceriello, Antonio
AU - Diem, Peter
AU - Felton, Anne Marie
AU - Grzeszczak, Wladyslaw
AU - Harno, Kari
AU - Kempler, Peter
AU - Satman, Ilhan
AU - Verges̀, Bruno
PY - 2012
Y1 - 2012
N2 - The role of glucagon-like peptide (GLP)-1-based treatment approaches for type 2 diabetes mellitus (T2DM) is increasing. Although self-monitoring of blood glucose (SMBG) has been performed in numerous studies on GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, the potential role of SMBG in GLP-1-based treatment strategies has not been elaborated. The expert recommendation suggests individualized SMBG strategies in GLP-1-based treatment approaches and suggests simple and clinically applicable SMBG schemes. Potential benefits of SMBG in GLP-1-based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education. Its length and frequency should depend on the clinical setting and the quality of metabolic control. It is considered to play an important role for the optimization of diabetes management in T2DM patients treated with GLP-1-based approaches.
AB - The role of glucagon-like peptide (GLP)-1-based treatment approaches for type 2 diabetes mellitus (T2DM) is increasing. Although self-monitoring of blood glucose (SMBG) has been performed in numerous studies on GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, the potential role of SMBG in GLP-1-based treatment strategies has not been elaborated. The expert recommendation suggests individualized SMBG strategies in GLP-1-based treatment approaches and suggests simple and clinically applicable SMBG schemes. Potential benefits of SMBG in GLP-1-based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education. Its length and frequency should depend on the clinical setting and the quality of metabolic control. It is considered to play an important role for the optimization of diabetes management in T2DM patients treated with GLP-1-based approaches.
KW - Diabetes
KW - Dipeptidyl peptidase-4 inhibitors
KW - Glucagon-like peptide-1 analogs
KW - Hypoglycemia
KW - Self-monitoring
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84878141828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878141828&partnerID=8YFLogxK
U2 - 10.1177/193229681200600323
DO - 10.1177/193229681200600323
M3 - Article
C2 - 22768899
AN - SCOPUS:84878141828
VL - 6
SP - 665
EP - 673
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
SN - 1932-2968
IS - 3
ER -